TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Serum urate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Operative mortality rate (< 30 days)
Endpoint domain: Mortality/survival
Primary endpoint: Low‐cardiac‐output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C‐reactive protein release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eccentric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-QOL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Weight (BW) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surrogate markers of tubular injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of subjects reporting adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: bronchial hyperresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response at exit to fluoxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 physical component score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SMFA dysfunction index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: overall risk for death
Endpoint domain: Mortality/survival
Primary endpoint: CCV events
Endpoint domain: Adverse events/effects
Primary endpoint: COPD exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: duration of maintenance at pH above 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of maintenance at pH above 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of maintenance at pH above 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visceral adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RA diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Local and regional recurrence (LRR)
Endpoint domain: Mortality/survival
Primary endpoint: NACCE
Endpoint domain: Mortality/survival
Primary endpoint: Disease Activity Score (DAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subendocardial perfusion (SEVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Catheter-related infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Median catheter survival
Endpoint domain: Mortality/survival
Primary endpoint: time to spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arrival at PACU time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair shedding reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: time of first flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean tear meniscus height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tear meniscus depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative reduction in VAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean change from baseline error score for the ADAS-cog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean score on the CIBIC+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mortality from any cause
Endpoint domain: Mortality/survival
Primary endpoint: livebirth rate
Endpoint domain: Mortality/survival
Primary endpoint: clinical pregnancy rate (PR)
Endpoint domain: Mortality/survival
Primary endpoint: rates of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from any cause within 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of mHLA-DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: exclusive breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes-related distress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence to self-care scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in attenuation between melanoma and naevi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Portal blood flow mean velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of early breastfeeding cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: clinically satisfactory restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisional hernia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative wound dehiscence incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted mean change from baseline HbA1c at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving HbA1c <7 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of reported hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of heart failure postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for rescue inotrope (adrenaline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Utilization of intra-aortic balloon pump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment satisfaction with PPS therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in IC symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Children's liking for a peer
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Symptom severity judgments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual cement observed on abutment surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean amount of sulcus surface covered by cement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central retinal thickness decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of injections received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Salivary fluoride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fluoride retention (AUC(0-120))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen (FIB) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: postoperative release of granulocyte elastase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: postoperative release of complement C3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial proximal to distal TGV ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in minimal luminal diameter (MLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma malondialdehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inhibition of ocular itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of ocular redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient assessment of comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinically acceptable SRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of notable vocal fold movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time from administration of sugammadex to train‐of‐four ratio 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status with comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PAI-1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of patient-physician end-of-life care communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of an ACP-discussion with physicians within 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptoms of anxiety in loved ones
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in EQ-5Dindex score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diabetes remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(120min) of glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(120min) of insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of UAC for diagnosing microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of diagnosing microalbuminuria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: bacteriological eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy Rate
Endpoint domain: Mortality/survival
Primary endpoint: DLQI scores of 0/1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Itch Numeric Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Work Productivity and Activity Impairment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: pruritus intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Primary end point event (cardiovascular death, non-fatal acute myocardial reinfarction, disabling stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma SAA concentration as a marker of severity in acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma NO3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary excretion of NO3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal clearance of NO3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: accuracy in the diagnosis of multiple sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity in the diagnosis of multiple sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity in the diagnosis of multiple sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: decrease in fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Component Score (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of histologically confirmed CIN or cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of colposcopy referrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Specificity of HPV DNA test with cytology triage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: freezing score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Load to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reduction of nasal eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean VE values during fibreoptic intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric insufflation during intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Ketosis achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary ketones level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyads' coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self‐efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: social QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depressive symptoms reduction (IDS-SR(30))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms reduction (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional binding potential value in the amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative and depression/anxiety symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Auditory brainstem response abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Neurologic sequelae
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral palsy detection
Endpoint domain: Adverse events/effects
Primary endpoint: Control of ocular symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient global assessments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time until fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSE (Multiscale Entropy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum pancreatic enzyme concentrations (amylase and lipase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage increase in PD diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible PD length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMD at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: blood cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AIR (Acute Insulin Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Whole-body insulin sensitivity (Matsuda index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC of active GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of watertight closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum levels of sST2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Head and arm circumference Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subscapular skinfold Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Needlestick or cut incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percent total body weight loss (%TBWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious device-/procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: disappearance of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalization of blood and urine amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospitalization duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3/4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HAC (Hazardous Alcohol Consumption)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of whitening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLABSI rate
Endpoint domain: Adverse events/effects
Primary endpoint: median visual analogue pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of postoperative hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Improvement in FMA (shoulder/elbow, wrist/hand)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in ARAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle protein synthetic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee society function and pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active straight leg raising
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LS T-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent EPS
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in menstrual blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of patients highly satisfied with their results
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cure of bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Δ Hct between cord blood at birth and capillary heel blood at 48 hours of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delirium-free days
Endpoint domain: Adverse events/effects
Primary endpoint: Use of physical restraints
Endpoint domain: Adverse events/effects
Primary endpoint: Time to randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of diagnosis for NGU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative crying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in API
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in total acne loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excellent response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes